Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +433.33%. A quarter ago, it was expected that this company would post a loss of $0.24 per share when it actually produced earnings of $0.14, delivering a surprise of +158.33%.Over the last four quarters, the ...

Enovis (ENOV) came out with quarterly earnings of $0.95 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.98 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +17.28%. A quarter ago, it was expected that this manufacturing and engineering company would post earnings of $0.67 per share when it actually produced earnings of $0.75, delivering a surprise of +11.94%.Over the last four ...

Privia Health (PRVA) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +67.87%. A quarter ago, it was expected that this physician practice management company would post earnings of $0.06 per share when it actually produced earnings of $0.05, delivering a surprise of -16.67%.Over the la ...

分组1 - Evolent Health reported quarterly earnings of $0.08 per share, exceeding the Zacks Consensus Estimate of $0.06 per share, compared to a loss of $0.02 per share a year ago, representing an earnings surprise of +28.00% [1] - The company posted revenues of $468.72 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 0.11%, and this is a decline from year-ago revenues of $646.54 million [2] - Evolent Health shares have declined approximately 30.8% since the beginning of the year, while the S&P 500 has only declined by 0.1% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.08 on revenues of $544.44 million, and for the current fiscal year, it is $0.39 on revenues of $2.39 billion [7] - The Zacks Industry Rank indicates that the Medical Info Systems sector is currently in the bottom 40% of over 250 Zacks industries, suggesting potential underperformance compared to higher-ranked industries [8]

分组1 - Hims & Hers Health, Inc. reported quarterly earnings of $0.07 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, but down from $0.11 per share a year ago, resulting in an earnings surprise of +227.10% [1] - The company posted revenues of $617.82 million for the quarter ended December 2025, which was 0.22% below the Zacks Consensus Estimate, compared to $481.14 million in the same quarter last year [2] - Hims & Hers Health shares have declined approximately 51.9% year-to-date, contrasting with the S&P 500's gain of 0.9% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.13 on revenues of $645.27 million, and for the current fiscal year, it is $0.55 on revenues of $2.73 billion [7] - The Medical Info Systems industry, to which Hims & Hers Health belongs, is currently ranked in the bottom 45% of over 250 Zacks industries, indicating potential underperformance compared to higher-ranked industries [8]

分组1 - Claritev Corporation reported a quarterly loss of $4.88 per share, which was worse than the Zacks Consensus Estimate of a loss of $3.96, representing an earnings surprise of -23.23% [1] - The company posted revenues of $246.55 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 2.13%, and showing an increase from $232.15 million year-over-year [2] - Claritev Corporation has surpassed consensus revenue estimates four times over the last four quarters, but has only exceeded consensus EPS estimates once during the same period [2] 分组2 - The stock has underperformed significantly, losing about 45.6% since the beginning of the year, while the S&P 500 has gained 0.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$3.75 on revenues of $243.21 million, and for the current fiscal year, it is -$14.26 on revenues of $992.62 million [7] - The Medical Info Systems industry, to which Claritev Corporation belongs, is currently ranked in the bottom 45% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

iRhythm Holdings, Inc. (IRTC) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +1,484.70%. A quarter ago, it was expected that this company would post a loss of $0.36 per share when it actually produced a loss of $0.06, delivering a surprise of +83.33%.Over the last four quarters, the ...

Core Insights - Hims & Hers Health, Inc. (HIMS) is set to report its fourth-quarter 2025 results on February 23, with expectations of a revenue increase of 28.7% year-over-year, but a significant drop in earnings per share (EPS) by 81.8% compared to the prior year [1][6][21] Group 1: Performance Factors - The company's fourth-quarter results are anticipated to reflect ongoing momentum in its personalized, multi-specialty platform strategy, including expansions into men's health and menopause care, which broaden its market and enhance customer engagement [3][4] - International expansion efforts, such as entering Canada and launching a Weight Loss Programme in the U.K., are expected to contribute to growth by capturing additional demand outside the U.S. [4] - The introduction of Labs for biomarker testing and personalized action plans is likely to improve cross-selling opportunities and customer retention [4] Group 2: Financial Estimates - The Zacks Consensus Estimate for revenues in Q4 2025 is $619.2 million, representing a 28.7% increase from the previous year [6] - The consensus estimate for EPS is 2 cents, indicating a significant decline of 81.8% from the prior year's figure [6] Group 3: Cost and Legal Challenges - Rising operating expenses due to aggressive marketing, technology investments, and infrastructure development may negatively impact fourth-quarter results [5] - Ongoing legal scrutiny regarding compounded semaglutide products, including litigation from Novo Nordisk, could create uncertainty and pressure growth in the weight-loss segment [5] Group 4: Stock Performance and Valuation - Hims & Hers shares have declined by 52.9% over the past three months, underperforming both the Medical Info Systems sector and the S&P 500 [10] - The company's forward price-to-sales (P/S) ratio is 1.3X, which is below the industry average of 3.7X and its five-year median of 2.7X, indicating a potential undervaluation relative to expected sales growth [15][17] Group 5: Long-Term Strategy - Hims & Hers' long-term investment strategy focuses on capital allocation and platform expansion, supported by an $870 million convertible senior notes offering that enhances financial flexibility for global expansion and strategic acquisitions [18] - The appointment of an AI veteran as CTO indicates a strategic shift towards building an AI-powered care platform, aimed at improving diagnostic precision and treatment personalization [19] - The combination of disciplined capital deployment, technology-driven infrastructure, and international expansion is expected to provide sustained revenue growth and margin expansion over the long term [19][20]

分组1 - Talkspace, Inc. reported quarterly earnings of $0.03 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, and showing an increase from $0.01 per share a year ago, representing an earnings surprise of +50.00% [1] - The company posted revenues of $63 million for the quarter ended December 2025, which missed the Zacks Consensus Estimate by 0.16%, compared to revenues of $48.72 million in the same quarter last year [2] - Talkspace shares have increased by approximately 8.3% since the beginning of the year, outperforming the S&P 500's gain of 0.5% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.01 on revenues of $67.3 million, and for the current fiscal year, it is $0.13 on revenues of $286 million [7] - The Zacks Industry Rank indicates that the Medical Info Systems sector is currently in the bottom 46% of over 250 Zacks industries, suggesting that the industry outlook may negatively impact stock performance [8] - The estimate revisions trend for Talkspace was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6]

Core Insights - Tempus AI, Inc. (TEM) is set to report its fourth-quarter 2025 results on February 24, with expectations of an 82.8% year-over-year revenue increase to $366.8 million [2][7] - The company reported an adjusted loss of 11 cents per share in the last quarter, which was better than the Zacks Consensus Estimate of a loss of 16 cents [1] - Tempus has seen a share price decline of 32.9% in the fourth quarter due to macroeconomic challenges, despite strong momentum from strategic acquisitions and product launches [3][7] Financial Performance - The Zacks Consensus Estimate for loss per share has remained unchanged at 2 cents over the past 30 days [2] - The company's earnings estimate revision trend shows consistent expectations for the current quarter and the next, with losses projected at -0.02 for Q4 and -0.13 for Q1 2026 [3] - In the previous quarter, Tempus achieved a gross profit improvement of 98.4% year-over-year, and adjusted EBITDA turned positive, indicating progress towards profitability [14] Market Position and Competitive Landscape - Tempus trades at a forward price-to-sales (P/S) ratio of 5.82X, which is above the industry average of 5.66X and higher than competitors like 10x Genomics (3.83X) and SOPHiA GENETICS (3.69X) [16] - The Zacks Medical Info Systems industry experienced a loss of 21.6% during the same period, while the S&P 500 gained 3.3% [4] Strategic Developments - Recent collaborations include a multi-year partnership with Whitehawk Therapeutics for oncology treatments and a selection by the Advanced Research Projects Agency for Health to provide testing services [8] - The Genomics segment is expected to show improvement due to growth in oncology testing and hereditary sequencing, while the Data and Services business is likely to benefit from strong demand for proprietary data licensing and AI solutions [9][10] - Tempus has enhanced its capabilities through the acquisition of Paige, an AI leader in digital pathology, and expanded its collaboration with Northwestern Medicine to integrate AI into clinical workflows [12] Future Outlook - The AI market is anticipated to grow rapidly, positioning Tempus to capitalize on emerging opportunities in healthcare [17] - Despite recent upsides, the company's premium valuation and lack of near-term profitability may limit immediate gains [18]